Psychiatric adverse events during vigabatrin therapy

Neurology

Volumn 53, Issue 7, 1999, Pages 1503-1511

  Levinson, Douglas F ^a,c   Devinsky, Orrin ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiepileptic drugs; Depression; Psychiatric adverse events; Psychosis; Vigabatrin

Indexed keywords

PLACEBO; VIGABATRIN;

AFFECTIVE NEUROSIS; AGGRESSION; AGITATION; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; FOCAL EPILEPSY; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MANIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SUICIDE ATTEMPT; TARDIVE DYSKINESIA;

EID: 0032716575     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1503     Document Type: Article

References (34)

1. Sander JWAS, Hart YM. Vigabatrin and behavior disturbances. Lancet 1990;335:57.
2. Sander JWAS, Hart YM, Trimble MR, Shorvon SD. Behavioral disturbances associated with vigabatrin therapy. Epilepsia 1991;32(suppl 1):12.
3. Sander JWAS, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54: 435-439.
4. Ring HA, Thomas LA, Trimble MR. Behavioural changes and vigabatrin: a European survey. Epilepsia 1993;34:119-120.
5. Thomas LA, Ring HA, Trimble MR. Vigabatrin and psychosis: a retrospective controlled study. Epilepsia 1993;34:116.
6. Trimble MR. The psychosis of epilepsy. New York: Raven Press, 1991.
7. Logsdail S, Toone B. Postictal psychosis: a clinical and phenomenological description. Br J Psychiatry 1988;152:246-252.
8. Ketter TA, Malow BA, Flamini R, White SR, Post RM, Theodore WH. Anticonvulsant withdrawal-emergent psychopathology. Neurology 1994;44:55-61.
9. French JA, Mosier M, Walker S, et al. A double-blind placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
10. Dean C, Mosier M, Penry P on behalf of the Vigabatrin Dose-Response Study Group. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999;40:74-82.
11. Ben-Menachem E, Persson LI, Schechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27(suppl 1):79S-85S.
12. Ring HA, Trimble MR, Costa DC, George MS, Verhoeff P, Eli PJ. Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. J Neurol Neurosurg Psychiatry 1992;55:758-761.
13. Betts T, Thomas L. Vigabatrin and behavior disturbances. Lancet 1990;335:606.
14. Betts T. Management of psychotic reactions related to use of vigabatrin. Epilepsia 1993;34:118.
15. Fernandez-Teruel A, Escorihuela RM, Boix F, Longoni B, Corda MG, Tobena A. Imipramine and desipramine decreased the GABA-stimulated chloride uptake, and antiGABAergic agents enhance their action in the forced swimming test in rats. Neuropsychobiology 1990;23:147-152.
16. Malatynska E, De Leon I, Allen D, Yamamura HI. Effects of amitriptyline on GABA-stimulated 36CI uptake in relation to a behavioral model of depression. Brain Res Bull 1995;37:53-59.
17. McKee RJW, Larkin JG, Brodie MJ. Acute psychosis with carbamazepine and sodium valproate. Lancet 1989;1:167.
18. Mizukami K, Naito Y, Yoshida M, Nakanishi T, Koizumi J. Mental disorders induced by carbamazepine. Jpn J Psychiatry Neurol 1990;44:59-63.
19. Friedman DL, Kastner T, Plummer AT, Ruiz MQ, Henning D. Adverse behavioral effects in individuals with mental retardation and mood disorders treated with carbamazepine. Am J Ment Retard 1992;96:541-546.
20. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 1980;136:354-358.
21. French JA. Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs. Epilepsia 1996;37(suppl 2):S23-S26.
22. Flierl A, Petzl G, Graf M, Froescher W, Mamoli B, Stefan H. Follow-up of 202 patients with focal epilepsy treated with new antiepileptic drugs (vigabatrin, lamotrigine, and felbamate). Epilepsia 1995;36(suppl 3):S109. Abstract.
23. Gudin MA, Sanchez C, del Real MA, et al. Lamotrigine and vigabatrin in difference seizure types. Epilepsia 1995;36(suppl 3):S109. Abstract.
24. Moelsae P, Rautaoja T. New antiepileptic drugs in mentally handicapped patients with intractable epilepsy. Eur J Neurol 1996;3(suppl 5):138. Abstract.
25. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996;313:1169-1174.
26. Kaelviaeinen R, Aeikiae M, Riekkinen PJ Sr. Vigabatrin monotherapy in newly diagnosed patients with epilepsy: two-year comparative follow-up of efficacy, safety, and cognitive effects. Epilepsia 1995;36(suppl 3):S105. Abstract.
27. de Feo MR, Mecarelli O, Marciani MG, et al. Vigabatrin monotherapy in newly diagnosed partial epilepsy: an open multicenter study. Epilepsia 1995;36(suppl 3):S105. Abstract.
28. Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional crossover study. Epilepsy Res 1996;25:257-262.
29. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-181. Letter.
30. Wilson EA, Brodie MJ, Wong ICK, Mawer GE, Sander JW. Severe and persistent visual field constriction associated with vigabatrin. BMJ 1997;314:1693. Letter.
31. Kraemer G, Scollo-Lavizzari G, Jallon P, et al. Vigabatrin-associated bilateral concentric visual field defects in four patients. Epilepsia 1997;38(suppl 8):179. Abstract.
32. Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects. BMJ 1998;316:232-233. Letter.
33. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
34. Beran RG, Berkovic SF, Buchanan N, et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996;5259-5265.